Phenylbutazone
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00812 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 31 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | rheumatoid arthritis | KG + DL |
| 2 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | KG + DL |
| 3 | brachydactyly-syndactyly syndrome | KG + DL |
| 4 | gout | KG + DL |
| 5 | sclerosing cholangitis | KG + DL |
| 6 | osteoarthritis susceptibility | KG + DL |
| 7 | osteoarthritis | KG + DL |
| 8 | acromesomelic dysplasia, Hunter-Thompson type | KG + DL |
| 9 | brachyolmia | KG + DL |
| 10 | myosclerosis | KG + DL |
| 11 | brachyolmia-amelogenesis imperfecta syndrome | KG + DL |
| 12 | pseudoachondroplasia | KG + DL |
| 13 | WHIM syndrome | KG + DL |
| 14 | arthropathy | KG + DL |
| 15 | heparin cofactor 2 deficiency | KG + DL |
| 16 | factor 5 excess with spontaneous thrombosis | KG + DL |
| 17 | antithrombin deficiency type 2 | KG + DL |
| 18 | trigeminal autonomic cephalalgia | KG + DL |
| 19 | thrombophilia | KG + DL |
| 20 | headache disorder | KG + DL |
| 21 | autoimmune hemolytic anemia | KG + DL |
| 22 | exostosis | KG + DL |
| 23 | juvenile arthritis due to defect in LACC1 | KG + DL |
| 24 | hypoalphalipoproteinemia | KG + DL |
| 25 | endocardial fibroelastosis | KG + DL |
| 26 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | KG + DL |
| 27 | disorder of GPI anchor biosynthesis | KG + DL |
| 28 | acquired aplastic anemia | KG + DL |
| 29 | brain small vessel disease 1 with or without ocular anomalies | KG + DL |
| 30 | thrombotic disease | KG + DL |
| 31 | rheumatoid nodulosis | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.